AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.
MetadataShow full item record
AbstractLetrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells. Phase III trials in both the advanced and early breast cancer setting have shown an improvement in disease-free survival compared with other compounds, including tamoxifen. Letrozole is well-tolerated, with the main adverse effects reported as hot flushes, arthritis, arthralgia and myalgia, and a trend towards increased risk of fracture.
CitationLetrozole: advancing hormone therapy in breast cancer. 2012, 8 (6):611-8 Womens Health
- A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
- Authors: Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL
- Issue date: 2003 Nov 6
- Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
- Authors: Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R
- Issue date: 2005 Aug 15
- Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
- Authors: Dunn C, Keam SJ
- Issue date: 2006
- Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
- Authors: Goss PE
- Issue date: 2006 Apr
- A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
- Authors: Breast International Group (BIG) 1-98 Collaborative Group., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A
- Issue date: 2005 Dec 29